Pharmacovigilance is the regulatory domain where gaps have the most direct patient safety consequences — and where compliance failures are most systematically under-detected.
The documentation requirements for post-market safety surveillance span FDA regulations (21 CFR 314.80, 314.98), ICH guidelines (E2A through E2F), EU Good Pharmacovigilance Practice (GVP) modules, and an expanding set of regional requirements. Each safety signal, adverse event report, periodic safety update, and risk management plan must satisfy specific regulatory standards.
Most pharmaceutical companies manage PV compliance through safety database systems — Argus, ArisGlobal, Veeva Vault Safety — that handle case processing and reporting workflows. What these systems don't do is evaluate whether the content of PV documentation actually satisfies regulatory requirements.
The PV Compliance Gap
A Periodic Safety Update Report (PSUR) or Periodic Benefit-Risk Evaluation Report (PBRER) isn't just a document that gets filed on schedule. ICH E2C(R2) specifies detailed content requirements: a comprehensive review of safety data, an integrated benefit-risk analysis, a signal evaluation section, and region-specific addenda. The regulatory expectation is that each PSUR/PBRER demonstrates an ongoing, systematic evaluation of the benefit-risk profile.
Manual review of PSUR/PBRER adequacy requires deep regulatory expertise and hours of evaluation. Regulatory teams typically focus on meeting submission deadlines — not systematically evaluating whether the content satisfies every ICH E2C(R2) requirement.
The result: PSURs that are filed on time but contain gaps that regulatory authorities identify during assessment. The EU's Pharmacovigilance Risk Assessment Committee (PRAC) routinely issues assessment reports identifying deficiencies in submitted PSURs — deficiencies that could have been caught before filing.
What AI-Powered PV Compliance Looks Like
Clinplex AI evaluates pharmacovigilance documentation against the full regulatory framework:
For PSURs/PBRERs: evaluation against ICH E2C(R2) content requirements, including completeness of the safety data review, adequacy of the benefit-risk analysis methodology, signal evaluation methodology, and consistency with the Reference Safety Information.
For Risk Management Plans (RMPs): evaluation against ICH E2E and EU GVP Module V requirements, including completeness of the safety specification, adequacy of the pharmacovigilance plan, and appropriateness of risk minimization measures.
For adverse event investigations: evaluation of case narratives against MedDRA coding accuracy, causality assessment methodology, and regulatory reporting timeline compliance under 21 CFR 314.80 and EU GVP Module VI.
Every finding includes the specific regulatory citation, severity rating, and remediation guidance.
The PV documentation challenge: Safety databases manage case processing workflows — intake, coding, causality assessment, submission. They do not evaluate whether the aggregate analyses, periodic reports, and risk management documents built from that data actually satisfy the regulatory content requirements. That's the gap AI fills.
Signal-to-Action: Cross-Domain PV Intelligence
Pharmacovigilance signals don't exist in isolation. A safety signal may require labeling changes (regulatory submissions), clinical trial protocol amendments (GCP), manufacturing process modifications (GMP), or updates to the risk management plan.
Clinplex's cross-domain intelligence connects PV signals to their downstream regulatory implications across the lifecycle. When a new safety signal is identified, the platform evaluates the impact on current labeling, active clinical trial protocols, and manufacturing risk assessments — providing a comprehensive view of the regulatory actions required across all domains.
This cross-domain connection is where the highest-consequence PV risks live. A signal that only triggers a PSUR update is manageable. A signal that simultaneously requires labeling changes, protocol amendments, and manufacturing modifications — across three regulatory domains — is where companies get caught without coordinated response plans.
Regulatory Frameworks for Pharmacovigilance
21 CFR 314.80/314.98 — Post-Market Reporting (US). ICH E2A — Clinical Safety Data Management. ICH E2B(R3) — Individual Case Safety Report Transmission. ICH E2C(R2) — Periodic Benefit-Risk Evaluation Report. ICH E2D — Post-Approval Safety Data Management. ICH E2E — Pharmacovigilance Planning. ICH E2F — Development Safety Update Report. EU GVP Module V — Risk Management Systems. EU GVP Module VI — Management of Adverse Reactions. EU GVP Module VII — Periodic Safety Update Report. EU GVP Module IX — Signal Management. REMS Guidance (FDA). CIOMS Reporting Standards.
Start with Your PV Documentation
Upload a PSUR, PBRER, risk management plan, or adverse event investigation for a free compliance assessment.
Try Free Analysis →